[go: up one dir, main page]

MX2018010096A - Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos. - Google Patents

Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.

Info

Publication number
MX2018010096A
MX2018010096A MX2018010096A MX2018010096A MX2018010096A MX 2018010096 A MX2018010096 A MX 2018010096A MX 2018010096 A MX2018010096 A MX 2018010096A MX 2018010096 A MX2018010096 A MX 2018010096A MX 2018010096 A MX2018010096 A MX 2018010096A
Authority
MX
Mexico
Prior art keywords
treatment
patients
lipid lowering
familial hypercholesterolemia
lowering therapy
Prior art date
Application number
MX2018010096A
Other languages
English (en)
Inventor
L Bisgaier Charles
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of MX2018010096A publication Critical patent/MX2018010096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

Métodos para el tratamiento de hipercolesterolemia familiar homocigota mediante la administración de gemcabeno como un adjunto a otra terapia de disminución de lípidos y/o dieta modificada.
MX2018010096A 2016-02-26 2017-02-27 Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos. MX2018010096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662300393P 2016-02-26 2016-02-26
PCT/US2017/019750 WO2017147598A1 (en) 2016-02-26 2017-02-27 Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy

Publications (1)

Publication Number Publication Date
MX2018010096A true MX2018010096A (es) 2018-11-09

Family

ID=59685647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010096A MX2018010096A (es) 2016-02-26 2017-02-27 Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.

Country Status (14)

Country Link
EP (1) EP3419614A4 (es)
JP (1) JP2019506423A (es)
KR (1) KR20180115722A (es)
CN (1) CN108697677A (es)
AU (1) AU2017224230A1 (es)
BR (1) BR112018067967A2 (es)
CA (1) CA3014919A1 (es)
HK (1) HK1257556A1 (es)
IL (1) IL261117A (es)
MX (1) MX2018010096A (es)
PH (1) PH12018501790A1 (es)
RU (1) RU2018133690A (es)
SG (2) SG11201806894PA (es)
WO (1) WO2017147598A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210093900A (ko) * 2018-10-18 2021-07-28 젬파이어 세러퓨틱스 인코포레이티드 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
EP3886871A4 (en) * 2018-11-30 2022-08-31 HDL Therapeutics, Inc. METHODS OF TREATMENT OF LIPID-RELATED DISEASES, INCLUDING XANTHOMA, CAROTID TENOSIS AND CEREBRAL ATHEROSCLEROSIS
EP4072672A1 (en) * 2019-12-10 2022-10-19 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN112138008B (zh) * 2020-09-30 2022-06-17 郑州大学 洛美他派在制备抗肿瘤药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
WO2007111992A2 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
AU2013207423B2 (en) * 2012-01-06 2017-10-12 Gemphire Therapeutics Inc. Methods of reducing risk of cardiovascular disease

Also Published As

Publication number Publication date
EP3419614A1 (en) 2019-01-02
CA3014919A1 (en) 2017-08-31
JP2019506423A (ja) 2019-03-07
SG10201912756XA (en) 2020-02-27
WO2017147598A1 (en) 2017-08-31
PH12018501790A1 (en) 2019-06-17
KR20180115722A (ko) 2018-10-23
HK1257556A1 (zh) 2019-10-25
BR112018067967A2 (pt) 2019-01-15
RU2018133690A (ru) 2020-03-26
IL261117A (en) 2018-10-31
RU2018133690A3 (es) 2020-05-29
AU2017224230A1 (en) 2018-08-30
EP3419614A4 (en) 2019-10-09
SG11201806894PA (en) 2018-09-27
CN108697677A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2016007351A (es) Terapia de combinacion para tratar cancer.
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
WO2016043874A3 (en) Combination therapy for treating cancer
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX377438B (es) Administracion de tasimelteon en condiciones de ayuno.
PH12018501790A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX366140B (es) Derivados de urea de piperidinas.
MX2016008042A (es) Derivados de imidazopirazinona.
HK1219896A1 (zh) 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物
EP4606387A3 (en) Methods of using interleukin-10 for treating diseases and disorders